Healthy volunteers needed to test drug interactions for cancer drug candidate
NCT ID NCT07438886
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study looks at how two common drugs—itraconazole (an antifungal) and ticagrelor (a blood thinner)—change the way the body processes AL3818, a potential cancer treatment. Sixteen healthy adults aged 18 to 45 will take AL3818 alone and then with each other drug. The goal is to measure drug levels in the blood, not to treat any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- catequentinib hydrochloride (AL3818)
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing GoBroad Hospital Ethics Review Committee
Beijing, Beijing Municipality, 102200, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can eye movements reveal the Brain's visual priorities?
- A new eye on the brain: could this tracer unlock Addiction's secrets?
- First look: can a new drug candidate pass early safety tests in humans?
- A painless, contact-free vibration sensor may detect hidden heart and lung problems
- Can a Two-Pathway pill improve ED treatment? a new trial puts the combo to the test
- Could a common drug shield the brain from Alzheimer's?